2023-12-012024-11-302024-11-30false12297962HANIF HEALTHCARE LIMITED2025-08-21falseiso4217:GBPxbrli:pure122979622023-11-30122979622024-11-30122979622023-12-012024-11-30122979622022-11-30122979622023-11-30122979622022-12-012023-11-3012297962bus:SmallEntities2023-12-012024-11-3012297962bus:AuditExempt-NoAccountantsReport2023-12-012024-11-3012297962bus:FullAccounts2023-12-012024-11-3012297962bus:PrivateLimitedCompanyLtd2023-12-012024-11-3012297962core:WithinOneYear2024-11-3012297962core:AfterOneYear2024-11-3012297962core:WithinOneYear2023-11-3012297962core:AfterOneYear2023-11-3012297962core:ShareCapital2024-11-3012297962core:SharePremium2024-11-3012297962core:RevaluationReserve2024-11-3012297962core:OtherReservesSubtotal2024-11-3012297962core:RetainedEarningsAccumulatedLosses2024-11-3012297962core:ShareCapital2023-11-3012297962core:SharePremium2023-11-3012297962core:RevaluationReserve2023-11-3012297962core:OtherReservesSubtotal2023-11-3012297962core:RetainedEarningsAccumulatedLosses2023-11-3012297962core:LandBuildings2024-11-3012297962core:PlantMachinery2024-11-3012297962core:Vehicles2024-11-3012297962core:FurnitureFittings2024-11-3012297962core:OfficeEquipment2024-11-3012297962core:NetGoodwill2024-11-3012297962core:IntangibleAssetsOtherThanGoodwill2024-11-3012297962core:ListedExchangeTraded2024-11-3012297962core:UnlistedNon-exchangeTraded2024-11-3012297962core:LandBuildings2023-11-3012297962core:PlantMachinery2023-11-3012297962core:Vehicles2023-11-3012297962core:FurnitureFittings2023-11-3012297962core:OfficeEquipment2023-11-3012297962core:NetGoodwill2023-11-3012297962core:IntangibleAssetsOtherThanGoodwill2023-11-3012297962core:ListedExchangeTraded2023-11-3012297962core:UnlistedNon-exchangeTraded2023-11-3012297962core:LandBuildings2023-12-012024-11-3012297962core:PlantMachinery2023-12-012024-11-3012297962core:Vehicles2023-12-012024-11-3012297962core:FurnitureFittings2023-12-012024-11-3012297962core:OfficeEquipment2023-12-012024-11-3012297962core:NetGoodwill2023-12-012024-11-3012297962core:IntangibleAssetsOtherThanGoodwill2023-12-012024-11-3012297962core:ListedExchangeTraded2023-12-012024-11-3012297962core:UnlistedNon-exchangeTraded2023-12-012024-11-3012297962core:MoreThanFiveYears2023-12-012024-11-3012297962core:Non-currentFinancialInstruments2024-11-3012297962core:Non-currentFinancialInstruments2023-11-3012297962dpl:CostSales2023-12-012024-11-3012297962dpl:DistributionCosts2023-12-012024-11-3012297962core:LandBuildings2023-12-012024-11-3012297962core:PlantMachinery2023-12-012024-11-3012297962core:Vehicles2023-12-012024-11-3012297962core:FurnitureFittings2023-12-012024-11-3012297962core:OfficeEquipment2023-12-012024-11-3012297962dpl:AdministrativeExpenses2023-12-012024-11-3012297962core:NetGoodwill2023-12-012024-11-3012297962core:IntangibleAssetsOtherThanGoodwill2023-12-012024-11-3012297962dpl:GroupUndertakings2023-12-012024-11-3012297962dpl:ParticipatingInterests2023-12-012024-11-3012297962dpl:GroupUndertakingscore:ListedExchangeTraded2023-12-012024-11-3012297962core:ListedExchangeTraded2023-12-012024-11-3012297962dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-12-012024-11-3012297962core:UnlistedNon-exchangeTraded2023-12-012024-11-3012297962dpl:CostSales2022-12-012023-11-3012297962dpl:DistributionCosts2022-12-012023-11-3012297962core:LandBuildings2022-12-012023-11-3012297962core:PlantMachinery2022-12-012023-11-3012297962core:Vehicles2022-12-012023-11-3012297962core:FurnitureFittings2022-12-012023-11-3012297962core:OfficeEquipment2022-12-012023-11-3012297962dpl:AdministrativeExpenses2022-12-012023-11-3012297962core:NetGoodwill2022-12-012023-11-3012297962core:IntangibleAssetsOtherThanGoodwill2022-12-012023-11-3012297962dpl:GroupUndertakings2022-12-012023-11-3012297962dpl:ParticipatingInterests2022-12-012023-11-3012297962dpl:GroupUndertakingscore:ListedExchangeTraded2022-12-012023-11-3012297962core:ListedExchangeTraded2022-12-012023-11-3012297962dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-12-012023-11-3012297962core:UnlistedNon-exchangeTraded2022-12-012023-11-3012297962core:NetGoodwill2024-11-3012297962core:IntangibleAssetsOtherThanGoodwill2024-11-3012297962core:LandBuildings2024-11-3012297962core:PlantMachinery2024-11-3012297962core:Vehicles2024-11-3012297962core:FurnitureFittings2024-11-3012297962core:OfficeEquipment2024-11-3012297962core:AfterOneYear2024-11-3012297962core:WithinOneYear2024-11-3012297962core:ListedExchangeTraded2024-11-3012297962core:UnlistedNon-exchangeTraded2024-11-3012297962core:ShareCapital2024-11-3012297962core:SharePremium2024-11-3012297962core:RevaluationReserve2024-11-3012297962core:OtherReservesSubtotal2024-11-3012297962core:RetainedEarningsAccumulatedLosses2024-11-3012297962core:NetGoodwill2023-11-3012297962core:IntangibleAssetsOtherThanGoodwill2023-11-3012297962core:LandBuildings2023-11-3012297962core:PlantMachinery2023-11-3012297962core:Vehicles2023-11-3012297962core:FurnitureFittings2023-11-3012297962core:OfficeEquipment2023-11-3012297962core:AfterOneYear2023-11-3012297962core:WithinOneYear2023-11-3012297962core:ListedExchangeTraded2023-11-3012297962core:UnlistedNon-exchangeTraded2023-11-3012297962core:ShareCapital2023-11-3012297962core:SharePremium2023-11-3012297962core:RevaluationReserve2023-11-3012297962core:OtherReservesSubtotal2023-11-3012297962core:RetainedEarningsAccumulatedLosses2023-11-3012297962core:NetGoodwill2022-11-3012297962core:IntangibleAssetsOtherThanGoodwill2022-11-3012297962core:LandBuildings2022-11-3012297962core:PlantMachinery2022-11-3012297962core:Vehicles2022-11-3012297962core:FurnitureFittings2022-11-3012297962core:OfficeEquipment2022-11-3012297962core:AfterOneYear2022-11-3012297962core:WithinOneYear2022-11-3012297962core:ListedExchangeTraded2022-11-3012297962core:UnlistedNon-exchangeTraded2022-11-3012297962core:ShareCapital2022-11-3012297962core:SharePremium2022-11-3012297962core:RevaluationReserve2022-11-3012297962core:OtherReservesSubtotal2022-11-3012297962core:RetainedEarningsAccumulatedLosses2022-11-3012297962core:AfterOneYear2023-12-012024-11-3012297962core:WithinOneYear2023-12-012024-11-3012297962core:Non-currentFinancialInstrumentscore:CostValuation2023-12-012024-11-3012297962core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-12-012024-11-3012297962core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-12-012024-11-3012297962core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-12-012024-11-3012297962core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-12-012024-11-3012297962core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-12-012024-11-3012297962core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-12-012024-11-3012297962core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-12-012024-11-3012297962core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-12-012024-11-3012297962core:Non-currentFinancialInstrumentscore:CostValuation2024-11-3012297962core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-11-3012297962core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-11-3012297962core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-11-3012297962core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-11-3012297962core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-11-3012297962core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-11-3012297962core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-11-3012297962core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-11-3012297962core:Non-currentFinancialInstrumentscore:CostValuation2023-11-3012297962core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-11-3012297962core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-11-3012297962core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-11-3012297962core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-11-3012297962core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-11-3012297962core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-11-3012297962core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-11-3012297962core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-11-3012297962bus:Director12023-12-012024-11-3012297962bus:Director22023-12-012024-11-3012297962core:FurnitureFittingsToolsEquipment2023-11-3012297962core:FurnitureFittingsToolsEquipment2023-12-012024-11-3012297962core:FurnitureFittingsToolsEquipment2024-11-30

HANIF HEALTHCARE LIMITED

Registered Number
12297962
(England and Wales)

Unaudited Financial Statements for the Year ended
30 November 2024

HANIF HEALTHCARE LIMITED
Company Information
for the year from 1 December 2023 to 30 November 2024

Directors

HANIF, Asim Rizwan
QAYUM, Zakia Begum

Registered Address

88 Deeds Grove
High Wycombe
HP12 3NZ

Registered Number

12297962 (England and Wales)
HANIF HEALTHCARE LIMITED
Balance Sheet as at
30 November 2024

Notes

2024

2023

£

£

£

£

Fixed assets
Intangible assets3328,053349,923
Tangible assets42,1051,582
Investments51,383,789-
1,713,947351,505
Current assets
Stocks640,00036,300
Debtors7141,344139,355
Cash at bank and on hand36,04851,130
217,392226,785
Creditors amounts falling due within one year8(830,629)(207,748)
Net current assets (liabilities)(613,237)19,037
Total assets less current liabilities1,100,710370,542
Creditors amounts falling due after one year9(1,099,976)(333,917)
Net assets73436,625
Capital and reserves
Called up share capital100100
Profit and loss account63436,525
Shareholders' funds73436,625
The financial statements were approved and authorised for issue by the Board of Directors on 21 August 2025, and are signed on its behalf by:
HANIF, Asim Rizwan
Director
Registered Company No. 12297962
HANIF HEALTHCARE LIMITED
Notes to the Financial Statements
for the year ended 30 November 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Functional and presentation currency
The financial statements are presented in sterling and this is the functional currency of the company.
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of pharmacy services and is recognised at the point the goods are sold or services are rendered.
Employee benefits
Short-term employee benefits are measured at the undiscounted amount expected to be paid in exchange for the employee's services to the company. Where employees have accrued short-term benefits which the entity has not paid by the balance sheet date, an accrual is recognised within creditors: amounts falling due within one year together with an associated expense in profit or loss. The liabilities are classified as current obligations in the statement of financial position because they are expected to be settled wholly within twelve months after the end of the period.
Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses. Goodwill, being the amount paid in connection with the acquisition of a business, is being amortized evenly over its estimated useful life of twenty years.
Tangible fixed assets and depreciation
All fixed assets are initially recorded at cost and subsequently at cost less depreciation. The depreciation is provided at the following rates :

Reducing balance (%)
Fixtures and fittings25
Office Equipment25
Investments
Investments in subsidiaries, associates and joint ventures are measured at cost less any accumulated impairment losses. Listed investments are measured at fair value where the difference between cost and fair value is material. Unlisted investments are measured at fair value unless the value cannot be measured reliably, in which case they are measured at cost less any accumulated impairment losses. Changes in fair value are included in the profit and loss account.
Stocks and work in progress
Inventories are valued at the lower of cost and estimated selling price (less any associated costs to enable such sales to complete). Stocks consists of unsold medicines at the year end.
Financial instruments
The company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments. Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument. Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously. Basic financial assets Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised. Basic financial liabilities Basic financial liabilities, including creditors are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised. Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortized cost using the effective interest method.
Share capital
Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new ordinary shares or options are shown in equity as a deduction, net of tax, from the proceeds.
2.Average number of employees

20242023
Average number of employees during the year79
3.Intangible assets

Goodwill

Total

££
Cost or valuation
At 01 December 23437,404437,404
At 30 November 24437,404437,404
Amortisation and impairment
At 01 December 2387,48187,481
Charge for year21,87021,870
At 30 November 24109,351109,351
Net book value
At 30 November 24328,053328,053
At 30 November 23349,923349,923
4.Tangible fixed assets

Fixtures & fittings

Office Equipment

Total

£££
Cost or valuation
At 01 December 232,0151,0493,064
Additions1191,1001,219
At 30 November 242,1342,1494,283
Depreciation and impairment
At 01 December 231,2712111,482
Charge for year211485696
At 30 November 241,4826962,178
Net book value
At 30 November 246521,4532,105
At 30 November 237448381,582
5.Fixed asset investments

Investments in groups1

Total

££
Cost or valuation
Additions1,383,7891,383,789
At 30 November 241,383,7891,383,789
Net book value
At 30 November 241,383,7891,383,789
At 30 November 23--

Notes

1Investments in group undertakings and participating interests
6.Stocks

2024

2023

££
Finished goods40,00036,300
Total40,00036,300
7.Debtors: amounts due within one year

2024

2023

££
Trade debtors / trade receivables113,621116,601
Other debtors26,39221,976
Prepayments and accrued income1,331778
Total141,344139,355
8.Creditors: amounts due within one year

2024

2023

££
Trade creditors / trade payables95,19092,677
Bank borrowings and overdrafts53,80724,996
Amounts owed to related parties601,283-
Taxation and social security24,51425,591
Other creditors55,83562,856
Accrued liabilities and deferred income-1,628
Total830,629207,748
9.Creditors: amounts due after one year

2024

2023

££
Bank borrowings and overdrafts1,099,976333,917
Total1,099,976333,917
Included in other creditors due within one and more than one year is an amount of £1,153,783 (2023 : £358,912) loan secured against the fixed and floating charge on the property or undertaking of the company.
10.Operating lease commitments
At 30/11/2024, the company had total commitments under non-cancellable operating leases over the remaining life of those leases of £5,963 (2023 : £6,460) and £13,000 (2023 : £13,000) of rent.
11.Related party transactions
Included in other creditors is an amount of £450 (2023 : £2,901) due to the director. A total of £39,000 dividends has been declared to the directors.
12.Departures from standards and their financial impact
These financial statements for the year ended 30 November 2024 are the first financial statements of Hanif Healthcare Ltd in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland. The date of transition to FRS 102 was 1 December 2023. The reported financial position and financial performance for the previous period are not affected by the transition to FRS 102.